HC Wainwright Reiterates Buy Rating for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $16.00 price target on the biopharmaceutical company’s stock.

Other equities analysts have also issued research reports about the stock. StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 price target on the stock. The Goldman Sachs Group began coverage on Esperion Therapeutics in a report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price target on the stock. Needham & Company LLC reissued a “buy” rating and set a $6.00 price objective on shares of Esperion Therapeutics in a research note on Friday, December 13th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $7.00 target price on shares of Esperion Therapeutics in a research report on Thursday, January 23rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Esperion Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $7.25.

Esperion Therapeutics Price Performance

ESPR opened at $1.86 on Tuesday. The business has a 50 day moving average price of $2.33 and a two-hundred day moving average price of $2.13. The company has a market capitalization of $366.49 million, a price-to-earnings ratio of -2.91 and a beta of 1.01. Esperion Therapeutics has a 1-year low of $1.58 and a 1-year high of $3.94.

Institutional Trading of Esperion Therapeutics

A number of hedge funds have recently modified their holdings of ESPR. Public Employees Retirement System of Ohio acquired a new position in Esperion Therapeutics during the third quarter valued at $606,000. Anson Funds Management LP purchased a new position in Esperion Therapeutics during the 3rd quarter valued at about $540,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Esperion Therapeutics by 71.0% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company’s stock valued at $1,174,000 after purchasing an additional 295,378 shares during the period. Wellington Management Group LLP lifted its position in shares of Esperion Therapeutics by 66.8% in the third quarter. Wellington Management Group LLP now owns 602,936 shares of the biopharmaceutical company’s stock worth $995,000 after purchasing an additional 241,512 shares in the last quarter. Finally, Wasatch Advisors LP boosted its holdings in shares of Esperion Therapeutics by 38.4% during the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock worth $38,521,000 after purchasing an additional 6,483,070 shares during the period. Hedge funds and other institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.